

# FIGO staging of endometrial cancer: 2023

Jonathan S. Berek<sup>1</sup> | Xavier Matias-Guiu<sup>2</sup> | Carien Creutzberg<sup>3</sup> | Christina Fotopoulou<sup>4</sup> | David Gaffney<sup>5</sup> | Sean Kehoe<sup>6</sup> | Kristina Lindemann<sup>7</sup> | David Mutch<sup>8</sup> | Nicole Concin<sup>9,10</sup> | Endometrial Cancer Staging Subcommittee, FIGO Women's Cancer Committee

<sup>1</sup>Stanford University School of Medicine, Stanford Women's Cancer Center, Stanford Cancer Institute, Stanford, California, USA

<sup>2</sup>Department of Pathology, Hospital U de Bellvitge and Hospital U Arnau de Vilanova, Universities of Lleida and Barcelona, Institut de Recerca Biomèdica de Lleida, Instituto de Investigación Biomédica de Bellvitge, Centro de Investigación Biomédica en Red de Cáncer, Barcelona, Spain

<sup>3</sup>Department of Radiation Oncology, Leiden University Medical Center, Leiden, The Netherlands

<sup>4</sup>Gynaecological Oncology, Department of Surgery and Cancer, Imperial College London, London, UK

<sup>5</sup>Department of Radiation Oncology, University of Utah, Salt Lake City, Utah, USA

<sup>6</sup>Oxford Gynaecological Cancer Centre, Churchill Hospital, Oxford, UK

<sup>7</sup>Department of Gynaecological Cancer, Oslo University Hospital, Faculty of Medicine, Institute of Clinical Medicine, University of Oslo, Oslo, Norway

<sup>8</sup>Division of Gynecologic Oncology, Washington University School of Medicine, St. Louis, Missouri, USA

<sup>9</sup>Department of Obstetrics and Gynecology, Medical University of Innsbruck, Innsbruck, Austria

<sup>10</sup>Kliniken Essen-Mitte, Essen, Germany

## Correspondence

Jonathan S. Berek, Stanford University School of Medicine, Stanford, CA, USA. Email: [jberek@stanford.edu](mailto:jberek@stanford.edu)

## Abstract

**Introduction:** Many advances in the understanding of the pathologic and molecular features of endometrial cancer have occurred since the FIGO staging was last updated in 2009. Substantially more outcome and biological behavior data are now available regarding the several histological types. Molecular and genetic findings have accelerated since the publication of The Cancer Genome Atlas (TCGA) data and provide improved clarity on the diverse biological nature of this collection of endometrial cancers and their differing prognostic outcomes. The goals of the new staging system are to better define these prognostic groups and create substages that indicate more appropriate surgical, radiation, and systemic therapies.

**Methods:** The FIGO Women's Cancer Committee appointed a Subcommittee on Endometrial Cancer Staging in October 2021, represented by the authors. Since then, the committee members have met frequently and reviewed new and established evidence on the treatment, prognosis, and survival of endometrial cancer. Based on these data, opportunities for improvements in the categorization and stratification of these factors were identified in each of the four stages. Data and analyses from the molecular and histological classifications performed and published in the recently developed ESGO/ESTRO/ESP guidelines were used as a template for adding the new subclassifications to the proposed molecular and histological staging system.

**Results:** Based on the existing evidence, the substages were defined as follows: *Stage I (IA1):* non-aggressive histological type of endometrial carcinoma limited to a polyp or confined to the endometrium; *(IA2)* non-aggressive histological types of endometrium involving less than 50% of the myometrium with no or focal lymphovascular space invasion (LVSI) as defined by WHO criteria; *(IA3)* low-grade endometrioid carcinomas limited to the uterus with simultaneous low-grade endometrioid ovarian involvement; *(IB)* non-aggressive histological types involving 50% or more of the myometrium with no LVSI or focal LVSI; *(IC)* aggressive histological types, i.e. serous,

Members of the FIGO Women's Cancer Committee and Endometrial Cancer Staging Subcommittee, 2021–2023, are listed in Appendix A.

This is an open access article under the terms of the [Creative Commons Attribution](https://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.

© 2023 The Authors. *International Journal of Gynecology & Obstetrics* published by John Wiley & Sons Ltd on behalf of International Federation of Gynecology and Obstetrics.

high-grade endometrioid, clear cell, carcinosarcomas, undifferentiated, mixed, and other unusual types without any myometrial invasion.

**Stage II (IIA):** non-aggressive histological types that infiltrate the cervical stroma; (IIB) non-aggressive histological types that have substantial LVSI; or (IIC) aggressive histological types with any myometrial invasion.

**Stage III (IIIA):** differentiating between adnexal versus uterine serosa infiltration; (IIIB) infiltration of vagina/parametria and pelvic peritoneal metastasis; and (IIIC) refinements for lymph node metastasis to pelvic and para-aortic lymph nodes, including micrometastasis and macrometastasis.

**Stage IV (IVA):** locally advanced disease infiltrating the bladder or rectal mucosa; (IVB) extrapelvic peritoneal metastasis; and (IVC) distant metastasis.

The performance of complete molecular classification (*POLEmut*, MMRd, NSMP, p53abn) is encouraged in all endometrial cancers. If the molecular subtype is known, this is recorded in the FIGO stage by the addition of "m" for molecular classification, and a subscript indicating the specific molecular subtype. When molecular classification reveals p53abn or *POLEmut* status in Stages I and II, this results in upstaging or downstaging of the disease (IIC<sub>m<sub>p53abn</sub></sub> or IAM<sub>POLEmut</sub>).

**Summary:** The updated 2023 staging of endometrial cancer includes the various histological types, tumor patterns, and molecular classification to better reflect the improved understanding of the complex nature of the several types of endometrial carcinoma and their underlying biologic behavior. The changes incorporated in the 2023 staging system should provide a more evidence-based context for treatment recommendations and for the more refined future collection of outcome and survival data.

#### KEYWORDS

cancer staging, endometrial cancer, endometrial cancer molecular staging, FIGO cancer staging, FIGO endometrial cancer staging

## 1 | INTRODUCTION

Since the publication of the last FIGO staging system for endometrial cancer in 2009, a considerable amount of new information has emerged that better defines the pathology and molecular findings as they relate to the type of endometrial carcinoma. In addition, new treatments, results of clinical trials, and prognostic and survival data that correlate with pathologic and surgical findings have been reported. Therefore, the FIGO Committee on Women's Cancer determined that modifications and updates in the staging system were warranted to reflect these new findings and data (Tables 1 and 2).

## 2 | PATHOLOGY

### 2.1 | Histological type

Histopathological findings are central features of the 2023 revision of the FIGO staging of endometrial carcinoma.

Histological tumor type is an important prognostic predictor in endometrial carcinoma. All endometrial carcinomas should be classified according to the 5th edition of *WHO Classification of Tumors, Female Genital Tumors*.<sup>1</sup> The following different histological types have been recognized: (1) endometrioid carcinoma (EEC), of low grade (grades 1 and 2) or high grade (grade 3); (2) serous carcinoma (SC); (3) clear cell carcinoma (CCC); (4) mixed carcinoma (MC); (5) undifferentiated carcinoma (UC); (6) carcinosarcoma (CS); (7) other unusual types, such as mesonephric-like; and (8) gastrointestinal mucinous type carcinomas. These different histological types have different molecular features, microscopic appearance, precursor lesions, and natural history. Previous studies have shown that histological typing may be essential in staging.<sup>2</sup> In this revised FIGO staging, non-aggressive histological types are composed of low-grade (grades 1 and 2) EECs, while aggressive histological types are composed of high-grade EECs (grade 3), SC, CCC, MC, UC, CS, and mesonephric-like and gastrointestinal type mucinous carcinomas. Importantly, high-grade EEC (grade 3) is a prognostically, clinically, and molecularly heterogeneous disease, and the tumor type that benefits most from applying molecular classification.<sup>3</sup> Molecular profiling within this high-grade EEC

TABLE 1 2023 FIGO staging of cancer of the endometrium.<sup>a,b</sup>

Stage	Description
Stage I	Confined to the uterine corpus and ovary <sup>c</sup>
IA	Disease limited to the endometrium OR non-aggressive histological type, i.e. low-grade endometrioid, with invasion of less than half of myometrium with no or focal lymphovascular space involvement (LVSI) OR good prognosis disease IA1 Non-aggressive histological type limited to an endometrial polyp OR confined to the endometrium IA2 Non-aggressive histological types involving less than half of the myometrium with no or focal LVSI IA3 Low-grade endometrioid carcinomas limited to the uterus and ovary <sup>c</sup>
IB	Non-aggressive histological types with invasion of half or more of the myometrium, and with no or focal LVSI <sup>d</sup>
IC	Aggressive histological types <sup>e</sup> limited to a polyp or confined to the endometrium
Stage II	Invasion of cervical stroma without extrauterine extension OR with substantial LVSI OR aggressive histological types with myometrial invasion
IIA	Invasion of the cervical stroma of non-aggressive histological types
IIB	Substantial LVSI <sup>d</sup> of non-aggressive histological types
IIC	Aggressive histological types <sup>e</sup> with any myometrial involvement
Stage III	Local and/or regional spread of the tumor of any histological subtype
IIIA	Invasion of uterine serosa, adnexa, or both by direct extension or metastasis IIIA1 Spread to ovary or fallopian tube (except when meeting stage IA3 criteria) <sup>c</sup> IIIA2 Involvement of uterine subserosa or spread through the uterine serosa
IIIB	Metastasis or direct spread to the vagina and/or to the parametria or pelvic peritoneum IIIB1 Metastasis or direct spread to the vagina and/or the parametria IIIB2 Metastasis to the pelvic peritoneum
IIIC	Metastasis to the pelvic or para-aortic lymph nodes or both <sup>f</sup> IIIC1 Metastasis to the pelvic lymph nodes IIIC1i Micrometastasis IIIC1ii Macrometastasis IIIC2 Metastasis to para-aortic lymph nodes up to the renal vessels, with or without metastasis to the pelvic lymph nodes IIIC2i Micrometastasis IIIC2ii Macrometastasis
Stage IV	Spread to the bladder mucosa and/or intestinal mucosa and/or distance metastasis
IVA	Invasion of the bladder mucosa and/or the intestinal/bowel mucosa
IVB	Abdominal peritoneal metastasis beyond the pelvis
IVC	Distant metastasis, including metastasis to any extra- or intra-abdominal lymph nodes above the renal vessels, lungs, liver, brain, or bone

Abbreviations: EEC, endometrioid carcinoma; LVSI, lymphovascular space involvement.

<sup>a</sup>Endometrial cancer is surgically staged and pathologically examined. In all stages, the grade of the lesion, the histological type and LVSI must be recorded. If available and feasible, molecular classification testing (*POLEmut*, MMRd, NSMP, p53abn) is encouraged in all patients with endometrial cancer for prognostic risk-group stratification and as factors that might influence adjuvant and systemic treatment decisions (Table 2).

<sup>b</sup>In early endometrial cancer, the standard surgery is a total hysterectomy with bilateral salpingo-oophorectomy via a minimally invasive laparoscopic approach. Staging procedures include infracolic omentectomy in specific histological subtypes, such as serous and undifferentiated endometrial carcinoma, as well as carcinosarcoma, due to the high risk of microscopic omental metastases. Lymph node staging should be performed in patients with intermediate-high/high-risk patients. Sentinel lymph node (SLN) biopsy is an adequate alternative to systematic lymphadenectomy for staging purposes. SLN biopsy can also be considered in low-/low-intermediate-risk patients to rule out occult lymph node metastases and to identify disease truly confined to the uterus. Thus, the ESGO-ESTRO-ESP guidelines allow an approach of SLN in all patients with endometrial carcinoma, which is endorsed by FIGO. In assumed early endometrial cancer, an SLN biopsy is an adequate alternative to systematic lymphadenectomy in high-intermediate and high-risk cases for the purpose of lymph node staging and can also be considered in low-/intermediate-risk disease to rule out occult lymph node metastases. An SLN biopsy should be done in association with thorough (ultrastaging) staging as it will increase the detection of low-volume disease in lymph nodes.

<sup>c</sup>Low-grade EECs involving both the endometrium and the ovary are considered to have a good prognosis, and no adjuvant treatment is recommended if all the below criteria are met. Disease limited to low-grade endometrioid carcinomas involving the endometrium and ovaries (Stage IA3) must be distinguished from extensive spread of the endometrial carcinoma to the ovary (Stage IIIA1), by the following criteria: (1) no more than superficial myometrial invasion is present (<50%); (2) absence of extensive/substantial LVSI; (3) absence of additional metastases; and (4) the ovarian tumor is unilateral, limited to the ovary, without capsule invasion/rupture (equivalent to pT1a).

<sup>d</sup>LVSI as defined in WHO 2021: extensive/substantial, ≥5 vessels involved.

<sup>e</sup>Grade and histological type

- Serous adenocarcinomas, clear cell adenocarcinomas, mesonephric-like carcinomas, gastrointestinal-type mucinous endometrial carcinoma, undifferentiated carcinomas, and carcinosarcomas are considered high-grade by definition. For EECs, grade is based on the proportion of solid areas: low grade = grade 1 ( $\leq 5\%$ ) and grade 2 (6%–50%); and high grade = grade 3 ( $> 50\%$ ). Nuclear atypia excessive for the grade raises the grade of a grade 1 or 2 tumor by one. The presence of unusual nuclear atypia in an architecturally low-grade tumor should prompt the evaluation of p53 and consideration of serous carcinoma. Adenocarcinomas with squamous differentiation are graded according to the microscopic features of the glandular component.
- Non-aggressive histological types are composed of low-grade (grade 1 and 2) EECs. Aggressive histological types are composed of high-grade EECs (grade 3), serous, clear cell, undifferentiated, mixed, mesonephric-like, gastrointestinal mucinous type carcinomas, and carcinosarcomas.
- It should be noted that high-grade EECs (grade 3) are a prognostically, clinically, and molecularly heterogeneous disease, and the tumor type that benefits most from applying molecular classification for improved prognostication and for treatment decision-making.<sup>3</sup> Without molecular classification, high-grade EECs cannot appropriately be allocated to a risk group and thus molecular profiling is particularly recommended in these patients. For practical purposes and to avoid undertreatment of patients, if the molecular classification is unknown, high-grade EECs were grouped together with the aggressive histological types in the actual FIGO classification.

<sup>f</sup>Micrometastases are considered to be metastatic involvement (pN1 (mi)). The prognostic significance of isolated tumor cells (ITCs) is unclear. The presence of ITCs should be documented and is regarded as pN0(i+). According to TNM8, macrometastases are  $> 2$  mm in size, micrometastases are 0.2–2 mm and/or  $> 200$  cells, and isolated tumor cells are  $\geq 0.2$  mm and  $\leq 200$  cells.<sup>39</sup> Based on staging established by FIGO and the American Joint Committee on Cancer (AJCC). *AJCC Cancer Staging Manual*. 8th ed. New York: Springer, 2017.

group is able to discriminate an excellent prognosis group (*POLEmut* in early-stage disease) from a bad prognosis group (p53 abnormal [p53abn]). It should be noted that recent data have demonstrated that high-grade EECs falling into the non-specific molecular profile (NSMP) group, especially when estrogen receptor (ER)-negative, also have a bad prognosis.<sup>4,5</sup> Furthermore, it is well established that in the mismatch repair deficient (MMRd) molecular subtype, grading does not matter. Thus, without molecular classification, high-grade EECs cannot be appropriately allocated to a risk group. Molecular profiling is of particular importance and highly recommended in high-grade EECs. For practical purposes and to avoid undertreatment of patients, if the molecular classification was unknown, high-grade EECs were grouped together with the aggressive histological types in the actual FIGO classification.

The 2020 WHO Classification<sup>1</sup> incorporates mucinous carcinoma as a variant of low-grade EECs because of its shared molecular features and natural history. It is distinguished from gastrointestinal type mucinous endometrial carcinoma, a rare type of tumor with different features and worse prognosis, which should be considered high-grade and included in the group of aggressive histological types.

## 2.2 | Tumor grade

Characterization of histological grade is very important in both the initial biopsy/curettage and the final hysterectomy specimen, especially in EEC and in NSMP.<sup>3</sup> SC, CCC, MC, UC, CS, and mesonephric-like and gastrointestinal mucinous type carcinomas are considered high-grade by definition.

For EECs, grading is prognostically significant.<sup>6,7</sup> The grading criteria for EECs are primarily based on architectural features.<sup>8</sup> In this revised FIGO staging scheme, the binary approach of *WHO Classification of Tumors, Female Genital Tumors*<sup>1</sup> has been adopted. In brief, low-grade EECs are subdivided into grade 1 and 2 tumors, which exhibit up to 5% and 6%–50% solid non-glandular growth, respectively.<sup>8</sup> In contrast, high-grade EECs (grade 3) are characterized by 50% or more solid component. This binary grading system allows easier clinical decision-making and has improved reproducibility,<sup>9</sup>

but it is prudent to remember that the three-tiered system is still of value in patients requesting fertility-preserving strategies. It is important to consider that nuclear atypia excessive for the grade raises the grade of a grade 1 or 2 tumor by one. Nuclear atypia in an architecturally low-grade EEC should be taken as an indication to rule out CS. EECs with squamous differentiation are graded according to the microscopic features of the glandular component. The International Society of Gynecological Pathologists (ISGYP) guidelines endorse the interpretation of a confluent microacinar pattern as solid growth, although there is no definitive scientific evidence in support of this.<sup>9</sup> Grading is especially important in NSMP endometrioid cancers. MMRd and *POLEmut* endometrioid cancers can seem high-grade because of their frequent mutations.

## 2.3 | Myometrial invasion

The extent of myometrial invasion has long been recognized as an essential prognostic risk factor.<sup>10</sup> It is recommended that the assessment of the percentage of myometrium involved should be expressed as the percentage of the overall myometrial thickness infiltrated by carcinoma using three categories: none;  $< 50\%$ ; or  $\geq 50\%$ .<sup>11–14</sup> The assessment of tumor invasion from adenomyosis is a controversial issue without strong scientific evidence.<sup>15</sup>

## 2.4 | Lymphovascular space invasion (LVSI)

LVSI should be assessed at the invasive front of the tumor.<sup>15,16</sup> It is crucial to distinguish LVSI from mimickers, such as a microcystic elongated and fragmented (MELF) pattern of myometrial invasion and retraction artifacts<sup>17–19</sup> that may occur in the setting of minimally invasive surgery. It is very important to distinguish “substantial” or “extensive” LVSI from “focal” or “no” LVSI.<sup>20–22</sup> Although determination of the precise number of involved vessels to discriminate between focal and extensive/substantial requires additional scientific evidence, for staging purposes the recommendation by WHO 2020 ( $\geq 5$  vessels) is adopted.<sup>1</sup>

TABLE 2 FIGO endometrial cancer stage with molecular classification.<sup>a</sup>

Stage designation	Molecular findings in patients with early endometrial cancer (Stages I and II after surgical staging)
Stage IA <sub>m</sub> <sub>POLEmut</sub>	<i>POLEmut</i> endometrial carcinoma, confined to the uterine corpus or with cervical extension, regardless of the degree of LVSI or histological type
Stage IIC <sub>m</sub> <sub>p53abn</sub>	p53abn endometrial carcinoma confined to the uterine corpus with any myometrial invasion, with or without cervical invasion, and regardless of the degree of LVSI or histological type

Abbreviation: LVSI, lymphovascular space involvement.

<sup>a</sup>When feasible, the addition of molecular subtype to the staging criteria allows a better prediction of prognosis in a staging/prognosis scheme. The performance of complete molecular classification (*POLEmut*, MMRd, NSMP, p53abn) is encouraged in all cases of endometrial cancer for prognostic risk-group stratification and as potential influencing factors of adjuvant or systemic treatment decisions. Molecular subtype assignment can be done on a biopsy, in which case it need not be repeated on the hysterectomy specimen. When performed, these molecular classifications should be recorded in all stages.

- Good prognosis: pathogenic *POLE* mutation (*POLEmut*)
- Intermediate prognosis: mismatch repair deficiency (MMRd)/microsatellite instability and no specific molecular profile (NSMP)
- Poor prognosis: p53 abnormal (p53abn) When the molecular classification is known:
- FIGO Stages I and II are based on surgical/anatomical and histological findings. In case the molecular classification reveals *POLEmut* or p53abn status, the FIGO stage is modified in the early stage of the disease. This is depicted in the FIGO stage by the addition of “m” for molecular classification, and a subscript is added to denote *POLEmut* or p53abn status, as shown below. MMRd or NSMP status do not modify early FIGO stages; however, these molecular classifications should be recorded for the purpose of data collection. When molecular classification reveals MMRd or NSMP, it should be recorded as Stage IA<sub>MMRd</sub> or Stage IA<sub>NSMP</sub> and Stage IIB<sub>MMRd</sub> or Stage IIB<sub>NSMP</sub>.
- FIGO Stages III and IV are based on surgical/anatomical findings. The stage category is not modified by molecular classification; however, the molecular classification should be recorded if known. When the molecular classification is known, it should be recorded as Stage III<sub>m</sub> or Stage IV<sub>m</sub> with the appropriate subscript for the purpose of data collection. For example, when molecular classification reveals p53abn, it should be recorded as Stage III<sub>m</sub><sub>p53abn</sub> or Stage IV<sub>m</sub><sub>p53abn</sub>.

The recognition of myometrial invasion and identification of LVSI in tumor tissue is dependent on appropriate sampling. Therefore, it is important to consider ISGYP recommendations, which state that one section per centimeter of the largest tumor dimension will suffice.<sup>23</sup>

## 2.5 | Cervical stromal invasion

Cervical stromal invasion is subjected to significant inter-observer variation<sup>24,25</sup> and strict criteria are recommended. Any invasion of the cervical stroma, identified at the level of or deeper than a benign endocervical crypt, should be considered cervical stromal invasion. Cervical glandular extension is not considered for staging.

## 2.6 | Adnexal involvement

Adnexal involvement has an impact on overall survival.<sup>26,27</sup> In the past, it was considered necessary to distinguish between endometrial carcinoma with ovarian metastasis and synchronous primary tumors of the endometrium and the ovary. In the case of high-grade tumors, ovarian involvement is almost always categorized as metastatic. However, for low-grade EECs, the situation is complex. Recent molecular studies have shown that there is a clonal relationship between the endometrial and ovarian tumor in the vast majority of cases, suggesting that the tumor arises in the endometrium, and secondarily extends to the ovary.<sup>28,29</sup> This clonal relationship is not always concordant with the clinical outcomes expected of metastatic endometrial carcinoma.

Accordingly, the 2020 edition of the WHO Classification<sup>1</sup> and the European Society of Gynecological Oncology (ESGO), European Society for Therapeutic Radiology and Oncology (ESTRO), and European Society of Pathology (ESP) guidelines<sup>30</sup> suggest conservative management (as if they were two independent primaries) for the group of patients with simultaneous low-grade carcinomas of the endometrium and the ovary if specific criteria are present, showing a good prognosis.<sup>32</sup> This revised 2023 FIGO staging for endometrial carcinoma endorses this view and establishes the category of Stage IA3 when the following criteria are met in a low-grade EEC: (1) no more than superficial myometrial invasion is present (<50%); (2) the absence of substantial LVSI; (3) the absence of additional metastases; and (4) the ovarian tumor is unilateral, limited to the ovary, without capsule invasion/breach (equivalent to pT1a). The cases not fulfilling these criteria should be interpreted as extensive spread of the endometrial carcinoma to the ovary (Stage IIIA1).

Tumor involvement of the fallopian tube should also be recorded and staged as IIIA1. Tubal involvement by endometrial carcinoma in the form of intramucosal spread has controversial prognostic significance, without strong scientific evidence. Pathologists should be careful in distinguishing tubal involvement by serous carcinoma from the coincidental presence of an independent serous tubal intraepithelial carcinoma; in these cases, appropriate sampling (SEE-FIM protocol),<sup>31</sup> as well as ancillary diagnostic techniques, such as immunohistochemistry and molecular pathology, are required. The presence of intraluminal tubal floating tumor fragments is a controversial issue, particularly in serous carcinoma, but is not considered for staging purposes. The same applies for positive washing cytology.

## 2.7 | Uterine serosal involvement

By following ISGYP recommendations,<sup>15</sup> uterine serosal involvement is defined as a tumor reaching submesothelial fibroconnective tissue or the mesothelial layer, regardless of whether tumor cells may or may not be present on the serosal surface of the uterus.

## 2.8 | Lymph node status

Lymph node status is an important prognostic factor for endometrial carcinoma. According to TNM8,<sup>33</sup> macrometastases are larger than 2 mm, micrometastases are 0.2–2 mm in size and/or more than 200 cells, and isolated tumor cells are up to 0.2 mm in size and up to 200 cells. A finding of isolated tumor cells does not upstage a carcinoma.<sup>33,34</sup> Ultrastaging is recommended for the analysis of sentinel lymph nodes.<sup>35–37</sup>

## 2.9 | Molecular classification

One of the major advances in the diagnosis and treatment of endometrial carcinoma during the past decade has been the ability to molecularly segregate and classify these carcinomas. Molecular features can be used to estimate risk of recurrence and hence survival.<sup>38–41</sup>

Perhaps the most impactful molecular classification is that proposed by The Cancer Genome Atlas (TCGA),<sup>31</sup> which classifies endometrial carcinomas into four categories: (1) *POLE*/ultramutated, with somatic inactivating hotspot mutations in the *POLE* exonuclease domain and a very high mutational burden (ultramutated). Irrespective of grade, *POLE* mutated tumors have an excellent prognosis; (2) microsatellite instability-high/hypermethylated, characterized by EECs or undifferentiated carcinomas with MMRd/microsatellite instability, have an intermediate prognosis; (3) somatic copy-number alteration high/serous like (SCNA-high) with a low mutation rate, nearly universal (95%) *TP53* mutations, and a highly unfavorable prognosis. Most of these tumors are serous carcinomas, but up to 25% are endometrioid (mostly high-grade) and carcinosarcomas; and (4) somatic copy-number alteration low (SCNA-low), which includes EECs and CCCs with low copy-number alterations and low mutational burden. In this intermediate group, estrogen receptor expression and histological grade impact the prognosis.<sup>4,5</sup>

TCGA molecular-based classification can be applied to clinical practice, by using a simplified surrogate that includes three immunohistochemical markers (p53, MSH6, and PMS2) and one molecular test (analysis for pathogenic *POLE* mutations). This surrogate approach classifies endometrial carcinoma into four groups: *POLEmut*; MMRd; p53abn; and NSMP. According to the 2020 edition of the WHO Classification,<sup>1</sup> abnormal p53 (mutation-type) staining is characterized by either strong nuclear expression in tumor cells (>80%), the complete absence of expression in tumor cells with retained internal control, or, rarely, unequivocal cytoplasmic expression.

Several studies have demonstrated the prognostic value of this TCGA-surrogate approach. *POLEmut* denotes a favorable prognosis. MMRd and NSMP indicate an intermediate prognosis, while p53abn indicates a poor prognosis. Most notably, data suggest that carcinomas falling into the *POLEmut* group may benefit from de-escalation of postoperative adjuvant therapy because of the consistently better outcome in these cases. In contrast, p53abn has a much worse prognosis, suggesting that some form of increased intensive therapy may be of benefit. Improved risk assessment by integrating molecular and clinicopathological factors in endometrial carcinoma has been demonstrated by many studies.<sup>42–50</sup> Furthermore, the TCGA surrogate approach has been verified by the molecular portion of PORTEC 3.<sup>38</sup>

There is a small subset of tumors (approximately 5%) that combine more than one molecular feature (e.g. *POLEmut* and p53abn or MMRd and p53abn), and they are referred to as “multiple classifiers.” In the case of multiple classifiers with *POLEmut* or MMRd and secondary p53 abnormality, the available scientific evidence indicates that they should not be classified as p53abn, because they retain the favorable prognosis of *POLEmut* or MMRd tumors; however, this is still an evolving field. Patients with both *POLEmut* and p53abn should be considered *POLEmut*; patients with both MMRd and p53abn should be considered MMRd.<sup>40</sup> For tumors with both a pathogenic *POLEmut* and MMRd, data are limited, and therefore screening for Lynch syndrome should be considered.

Integrating all currently available evidence, FIGO has taken the position that, when feasible, the addition of molecular subtype evaluation to the staging criteria should be performed as it allows a better prediction of prognosis in a staging/prognosis scheme (Table 2). The performance of complete molecular classification (*POLEmut*, MMRd, NSMP, p53abn) is encouraged in all cases of endometrial carcinoma for prognostic risk-group stratification and as potential influencing factors for adjuvant or systemic treatment decisions. Molecular subtype assignment can be conducted on a biopsy specimen, in which appropriate handling and control of fixation conditions may allow for a better performance of immunohistochemical and molecular techniques than on the final hysterectomy specimen.

The molecular characterization of endometrial cancer and its clinical relevance is a rapidly evolving field and changes can continue to occur based on incoming data. As noted, several groups have shown that molecular subtypes of endometrial cancer have a substantial impact on prognosis, recurrence, and survival outcomes in various cohorts of patients.<sup>30</sup> Depending on the molecular profile, adjuvant strategies that would de-escalate or intensify treatments after surgery are being defined. With respect to systemic treatment in primary advanced and recurrent endometrial cancer, two randomized Phase III trials (ENGOT-en6/GOG-3031/RUBY and NRG-GY018/Keynote-868) have demonstrated a statistically significant and unprecedented PFS advantage with the addition of an immune checkpoint inhibitor (ICI) (dostarlimab or pembrolizumab, respectively) to standard carboplatin/paclitaxel chemotherapy followed by ICI maintenance therapy in MMRd patients with a hazard ratio (HR) of 0.28 (95% confidence interval [CI] 0.16–0.5) and 0.30 (95% CI 0.19–0.48), respectively.<sup>51,52</sup> Several clinical trials investigating adapted adjuvant

treatment after surgery or different systemic treatment options in patients with advanced/recurrent endometrial carcinoma based on molecular profiles are in progress.

### 3 | FIGO STAGING OF ENDOMETRIAL CANCER

#### 3.1 | Stage I

The 2023 revised FIGO staging system includes major changes to Stage I. In most cases, Stage I is restricted to tumors confined to the uterine corpus, characterized by non-aggressive histological types (i.e. low-grade EEC), the absence of substantial/extensive LVSI, or aggressive histological types without myometrial invasion.

Stage IA1 tumors include those that are limited to an endometrial polyp or confined to the endometrium of non-aggressive histological types (i.e. low-grade EECs). Stage IA2 includes tumors of non-aggressive histological type involving up to 50% of the myometrium, with no LVSI or focal LVSI. Stage IA3 tumors are low-grade endometrioid carcinomas limited to the uterus with simultaneous low-grade endometrioid ovarian involvement, if the following criteria are met: (1) no more than superficial myometrial invasion is present (<50%); (2) the absence of substantial/extensive LVSI; (3) the absence of additional metastases; and (4) unilateral ovarian tumors, limited to the ovary, without capsule invasion/rupture (equivalent to pT1a).

Stage IB tumors represent non-aggressive histological types (i.e. low-grade EECs) with invasion of 50% or more of the myometrium, and with no or focal LVSI.

Stage IC tumors are aggressive tumor types within a polyp or confined to the endometrium without myometrial invasion.

The rationale for establishing these categories is evidence-based. Endometrial carcinomas limited to endometrial polyps or confined to the endometrium (any histology subtypes) are associated with a good prognosis.<sup>53,54</sup> A staging operation is necessary to establish this category. A significant proportion ( $\geq 40\%$ ) of high-grade tumors (particularly serous carcinomas) assumed to be limited to a polyp or the endometrium have occult lymph node and/or peritoneal involvement when appropriately staged and hence are actually Stage III disease.<sup>55-57</sup>

Low-grade EECs are associated with a good prognosis when they are limited to the uterine corpus and there is no LVSI or focal LVSI.<sup>2,22,58-62</sup>

There is a subset of patients with low-grade endometrioid carcinomas involving the endometrium and the ovaries, which are associated with a good prognosis.<sup>63-65</sup> They were previously described as synchronous independent tumors, but molecular analysis has established a common clonal origin.<sup>28,29</sup> FIGO endorsed the criteria by WHO and ESGO-ESTRO-ESP guidelines to identify this group of tumors that are categorized as Stage IA3.<sup>1,30</sup>

The absence of LVSI and focal LVSI have been related to a good prognosis in opposition to substantial/extensive LVSI in low-grade

EECs restricted to the uterus.<sup>22,60-62</sup> The criteria for LVSI follow the rules of WHO.<sup>1</sup> Accordingly, LVSI should fall into one of the following three categories: "LVSI negative" (0 vessels); "LVSI focal" (<5 vessels); or "LVSI substantial/extensive" ( $\geq 5$  vessels).

#### 3.2 | Stage II

The revised staging system includes major changes to Stage II. The number of women with Stage II tumors will markedly increase under the new staging system. Stage IIA tumors include non-aggressive histological that have invasion of the cervical stroma. Stage IIB now represents cases that include non-aggressive histological types with substantial LVSI as defined by the WHO 2021 report, regardless of local tumor spread. An extensive body of literature supports these findings. Randomized trials, prospective cohort studies, large database series, and single-institution reports consistently demonstrate that LVSI is an independent and strong prognostic factor for the recurrence of endometrial carcinoma.<sup>66-69</sup> A retrospective registry study of more than 1500 patients from Sweden with Stage I-III identified LVSI as the strongest independent risk factor for lymph node metastases and decreased survival, even in the absence of lymph node metastases in patients with endometrioid adenocarcinomas.<sup>67</sup>

Stage IIC tumors represent aggressive histological types with any myometrial involvement, while aggressive histological types without myometrial involvement are Stage IC. Aggressive histological types include high-grade endometrioid, serous adenocarcinomas, clear cell adenocarcinomas, mesonephric-like carcinomas, gastrointestinal-type mucinous endometrial carcinoma, undifferentiated carcinomas, and carcinosarcomas. Once again, randomized trials, prospective cohort studies, large database series, and retrospective reports consistently demonstrate that aggressive histological types have a markedly higher rate of relapse.<sup>70,71</sup>

Improved risk assessment by integrating molecular and clinicopathological factors in early-stage endometrial carcinoma has been demonstrated by many studies.<sup>38,39,41-47,72</sup>

#### 3.3 | Stage III

In Stage III, the tumor has spread locally or regionally. The revised subclassifications aim to better reflect the clinical picture and prognosis and enable a more appropriate treatment decision-making process. The differences from the previous staging system are summarized below.

First, differentiation between adnexal (IIIA1) versus uterine serosa infiltration (IIIA2) in Stage IIIA is defined to better reflect tumor behavior, especially in high-grade and non-endometrioid carcinomas.

Second, Stage IIIB is now divided into two substages. Stage IIIB1 aligns with the previous Stage IIIB disease and is characterized by involvement of the vagina and/or the parametria. Involvement of

the pelvic peritoneum is now classified as IIIB2 (previous Stage IV) to better reflect clinical treatment decisions in terms of indication for surgery versus non-surgical first-line treatments for patients with advanced stage disease. These treatment decisions vary significantly in cases with limited pelvic versus extensive/extrapelvic peritoneal carcinomatosis. The anatomical landmark of the pelvis is the line between the anterior superior iliac spines.

Third, Stage IIIC is further divided into micrometastasis (IIIC1i, IIIC2i) and macrometastasis to the lymph nodes (IIIC1ii, IIIC2ii), while isolated tumor cells (ITC) are not considered metastatic and regarded as pN0(i+). The substaging is based on the better prognosis in those patients who have micrometastasis to the lymph nodes.<sup>73-77</sup> This subcategorization also reflects the increasing utilization of the sentinel lymph node technique and ultrastaging, which allows improved identification of small volume disease, including micrometastasis. A reasonable approach for the surgical designation of Stage III versus Stage IV is the upper limit of the para-aortic lymph node metastasis to the renal vessels bilaterally.

Finally, low-grade EECs involving both the endometrium and ovary and matching specific criteria are no longer classified as Stage III but as Stage IA3 tumors, because they show evidence of a clonal relationship and can be considered to have an overall good prognosis.<sup>28</sup> For those cases, no adjuvant treatment is recommended. Stage IA3 excludes cases with adnexal involvement and more than 50% myometrial invasion, presence of substantial LVSI, bilateral ovarian involvement, capsule breach, and presence of additional metastatic lesions. These cases remain as Stage III and require adjuvant treatment as before.

### 3.4 | Stage IV

The main change to this part of the FIGO staging system is the addition of an extra substage for those presenting with extrapelvic peritoneal metastasis, what is now classified as Stage IVB, and is distinguished from those with peritoneal involvement that does not extend beyond the pelvis, which is Stage IIIB2. Local invasion of bladder mucosa and/or intestinal/bowel mucosa remains Stage IVA, while distant metastases, including to any extra-abdominal lymph nodes or intra-abdominal lymph nodes above the renal vessels to the lungs, liver, brain, or bone, have now become Stage IVC.

Peritoneal carcinomatosis is overall rare (detected in approximately 2% of all patients with endometrial carcinomas) and these patients should be distinguished from those with distant metastases.<sup>78,79</sup>

### 3.5 | FIGO staging with molecular classification

When feasible, the addition of molecular subtype to the staging criteria allows a better prediction of prognosis in a staging/prognosis scheme. The performance of a complete molecular classification surrogate (*POLEmut*, MMRd, NSMP, p53abn) is encouraged in all cases of endometrial carcinoma for prognostic risk-group stratification

and as potential influencing factors for adjuvant and systemic treatment decisions.

*POLEmut* denotes a favorable prognosis. MMRd and NSMP indicate an intermediate prognosis and therefore do not alter the stage, while p53abn indicates a poor prognosis.

In early endometrial cancer, the presence of pathogenic *POLE* mutations or of p53 abnormalities now modifies the FIGO stage. For Stage I and II tumors based on surgical/anatomical and histological findings, a *POLEmut* endometrial carcinoma, confined to the uterine corpus or with cervical extension, regardless of the degree of LVSI or histological type, is now classified as Stage IA<sub>m<sub>POLEmut</sub></sub>, whereas a p53abn endometrial carcinoma confined to the uterine corpus with any myometrial invasion, with or without cervical invasion and regardless of the degree of LVSI, is classified as Stage IIC<sub>m<sub>p53abn</sub></sub>. Although scientific evidence is limited, in the unusual situation when a low-grade EEC confined to the uterus is p53abn, the tumor is upstaged to IIC2<sub>m<sub>p53abn</sub></sub>. In the case of multiple classifiers with *POLEmut* or MMRd and secondary p53 abnormality, tumors should be considered as *POLEmut* or MMRd, and staged accordingly. The RAINBO program is a platform of four international clinical trials and an overarching research program that will address refining adjuvant treatment in endometrial cancer based on molecular features ([clinicaltrials.gov](http://clinicaltrials.gov) NCT05255653).

Advanced endometrial cancer stage based on surgical and/or clinicopathological features is not altered after additional molecular characterization, although more prognostic information and treatment directions are obtained by knowledge of the molecular classification. Thus, Stage III and IV tumors, for which molecular classification reveals p53abn, should be recorded as Stage III<sub>m<sub>p53abn</sub></sub> or Stage IV<sub>m<sub>p53abn</sub></sub>, respectively, for the purposes of data collection. Furthermore, Stage III and IV tumors, for which molecular classification reveals MMRd, should be recorded as Stage III<sub>m<sub>MMRd</sub></sub> or Stage IV<sub>m<sub>MMRd</sub></sub>, respectively, for the purpose of data collection and in view of its predictive value for ICI treatment and the demonstrated substantial progression-free survival and preliminary overall survival benefit. Advanced stage *POLEmut* endometrial carcinomas are a very rare category and although the clinical behavior seems favorable, this is based on anecdotal evidence, and for now these are classified as Stage III<sub>m<sub>POLEmut</sub></sub> or Stage IV<sub>m<sub>POLEmut</sub></sub>.

## 4 | DISCUSSION

The purpose of this revision of the FIGO endometrial cancer staging system is to incorporate the essential new published evidence as summarized above. The goal is to improve the clarity of the diverse biological nature of endometrial carcinomas with differing prognostic outcomes, better define these prognostic groups, and create substages that yield more appropriate surgical, radiation, and systemic therapies. As with all staging systems, the evolution of the updated classification must be based on the results of clinical studies.

The committee felt that the risk stratification, including the molecular classification that has recently been developed by



ESGO, ESTRO, and ESP helps to better define the prognosis and therapeutic approaches for these diseases.<sup>80,81</sup> Therefore, it was determined that notation of the molecular classification, when performed, should be included to stage the patient's disease. Notwithstanding the fact that these tests may not be available in some settings, the molecular findings are sufficiently prognostic that treatment might be modified in those patients for whom this information is obtained.

The inclusion of molecular measures for endometrial cancer follows the work done with breast cancer staging in 2018, when, along with tumor grade, several molecular assays results—estrogen receptor status, progesterone receptor status, and Her2*neu*—were added to the staging system to reflect the impact on prognosis of these significant molecular parameters.<sup>34</sup>

In summary, the current modifications to the endometrial staging system have been made to further define the differences in prognosis and survival that have been reported since the 2009 system was published. The following changes have been incorporated into the updated endometrial cancer staging system:

- Stage I: (IA1) non-aggressive histological type limited to an endometrial polyp or confined to the endometrium; (IA2) non-aggressive histological types involving less than half the myometrium with no or focal LVSI as defined by the WHO criteria; (IA3) low-grade endometrioid carcinomas limited to the uterus with simultaneous low-grade endometrioid ovarian involvement; (IB) non-aggressive histological types involving one half or more of the myometrium with no or focal LVSI; and (IC) aggressive histological types limited to a polyp or confined to the endometrium.
- Stage II: (IIA) tumors that infiltrate the endocervical stroma, or (IIB) have substantial LVSI or (IIC) aggressive histological types, i.e. serous, clear cell, carcinosarcomas, undifferentiated, mixed, gastrointestinal-type mucinous endometrial carcinoma, and mesonephric-like carcinomas with any myometrial invasion.
- Stage III: (IIIA1) differentiation between adnexal versus (IIIA2) uterine serosa involvement; (IIIB1) vaginal and/or parametrial involvement and (IIIB2) pelvic peritoneal carcinomatosis; refinements are defined within Stage IIIC to reflect the extent of pelvic and abdominal lymph node metastases with (IIIC1i) micrometastasis and (IIIC2ii) macrometastasis.
- Stage IV: (IVA) reflects locally infiltrative, (IVB) extrapelvic peritoneal metastasis, and (IVC) distant metastatic disease.

When performed, the *POLEmut* and *p53abn* molecular groups can increase or decrease the stage of endometrial cancer in Stages I and II. No changes occur through the molecular staging in Stages III and IV. Stage III and IV cases, for which the molecular classification is known, should be recorded as Stage III<sub>m</sub> and Stage IV<sub>m</sub> with the specification of the molecular class for the purpose of data collection. Based on these molecular assays, an “m” notation is always required to indicate that the stage is modified in case of early stages or recorded in case of advanced stages.

## AUTHOR CONTRIBUTIONS

Jonathan S. Berek was responsible for the conceptualization, investigation, methodology, project administration, supervision, visualization, writing the original draft, and reviewing and editing the manuscript. Xavier Matias-Guiu, Carien Creutzberg, Christina Fotopoulou, David Gaffney, Sean Kehoe, Kristina Lindemann, David Mutch, and Nicole Concin were responsible for the conceptualization, investigation, methodology, writing the original draft, and reviewing and editing the manuscript.

## ACKNOWLEDGMENTS

We dedicate this staging system to all women diagnosed with endometrial cancer in the hope that it will help to improve their care and treatment. The authors and committee members express their gratitude to Jeanne A. Conry, MD, PhD, FIGO President, and Mary Ann Lumsden, MD, FIGO CEO, for their guidance and support.

## CONFLICTS OF INTEREST STATEMENT

All funding stated here is unrelated to the present document. JSB received research funds from Eisai, Immunogen, Karyopharm, and Tesaro (paid to the institution); he participated in the Data Safety Monitoring Board or Advisory Board of Merck and Novocure. CC participated in the Data Safety Monitoring Board of Merck and received compensation for her time; she was Chair of the Endometrial Committee of the Gynecological Cancer Intergroup (GCIG) and Member of the Guidelines Committee of the European Society of Gynecological Oncology (ESGO); her institution received the Oncentra Research Platform for a clinical study from Elekta. CF received payment or honoraria for her participation in the Advisory Boards from Roche, AstraZeneca/MSD, Clovis, Tesaro, Ethicon, and GSK; she received support for attending meetings and/or travel from Roche and GSK. DG received an NCI UG1 LAPS grant for NCI clinical trials and a grant from Elekta for a clinical trial; he received payment or honoraria for attending the ANZGOG annual meeting; he was Chair for the DSMC Cervix Trial for Merck; he was Co-Chair of the Gynecology Committee of NRG Oncology. SK participated in the Advisory Board for Truscreen Ltd; he was a Council Member of the British Gynaecological Cancer Society and a Trustee for OVACOME. KL received a research grant from GSK; she received payment or honoraria from Eisai, GSK, and Nycodex; she participated in the Data Safety Monitoring Board or Advisory Board of Eisai, GSK, AstraZeneca, and MSD; she was on the Board of NSGO-CTU. NC received grants or contracts from the European Commission (FP7 Framework Program); she received consulting fees from Akesobio, Eisai, GSK, AstraZeneca, Mersana, Seattle Genetics, eTheRNA Immunotherapies NV, Seagen, and Immunogen; she received payment or honoraria for lectures or presentations from GSK, Kartos, MSD, Medscape Oncology, and TouchIME; she received support for attending meetings and/or travel from Roche, Genmab, and Armgen; she participated in a Data Safety Monitoring Board or Advisory Board of Akesobio, Eisai, GSK, AstraZeneca, Mersana, Seattle Genetics, eTheRNA Immunotherapies NV, Seagen, and Immunogen; she was ESGO President and Co-Chair of ENGOT

Early Drug Development Network. XM-G and DM have no conflicts of interest.

## DATA AVAILABILITY STATEMENT

Data sharing is not applicable to this article as no new data were created or analyzed in this study.

## REFERENCES

- WHO Classification of Tumours Editorial Board. *Female Genital Tumours, WHO Classification of Tumours*. Vol 4. 5th ed. IARC Press; 2020.
- Barlin JN, Soslow RA, Lutz M, et al. Redefining stage I endometrial cancer: incorporating histology, a binary grading system, myometrial invasion, and lymph node assessment. *Int J Gynecol Cancer*. 2013;23(9):1620-1628.
- Bosse T, Nout RA, McAlpine JN, et al. Molecular classification of grade 3 endometrioid endometrial cancers identifies distinct prognostic subgroups. *Am J Surg Pathol*. 2018;42(5):561-568.
- Jamieson A, Huvila J, Chiu D, et al. Grade and estrogen receptor expression identify a subset of no specific profile endometrial carcinomas at a very low risk of disease specific death. *Mod Pathol*. 2023;36(4):100212. doi:10.1016/j.modpat.2022.100085
- Vermij L, Jobson JJ, Leon-Castillo A, et al. Prognostic refinement of NSMP high-risk endometrial cancers using oestrogen receptor immunohistochemistry. *Brit J Cancer*. 2023;128:1360-1368. doi:10.1038/s41416-023-02141-0
- Colombo N, Creutzberg C, Amant F, et al. ESMO-ESGO-ESTRO consensus conference on endometrial cancer: diagnosis, treatment and follow-up. *Ann Oncol*. 2016;27(1):16-41.
- Abeler VM, Kjørstad KE, Berle E. Carcinoma of the endometrium in Norway: a histopathological and prognostic survey of a total population. *Int J Gynecol Cancer*. 1992;2(1):9-22.
- FIGO Committee on Gynecological Cancer. Revised FIGO staging for carcinoma of the vulva, cervix and endometrium. *Int J Gynecol Obstet*. 2009;105:103-104.
- Soslow RA, Tornos C, Park KJ, et al. Endometrial carcinoma diagnosis: use of FIGO grading and genomic subcategories in clinical practice: recommendations of the International Society of Gynecological Pathologists. *Int J Gynecol Pathol*. 2019;38(Suppl 1):S64-S74.
- Creasman WT, Morrow CP, Bundy BN, Homesley HD, Graham JE, Heller PB. Surgical pathologic spread patterns of endometrial cancer. A gynecologic oncology group study. *Cancer*. 1987;60(8 Suppl):2035-2041.
- Lindauer J, Fowler JM, Manolitsas TP, et al. Is there a prognostic difference between depth of myometrial invasion and the tumor-free distance from the uterine serosa in endometrial cancer? *Gynecol Oncol*. 2003;91(3):547-551.
- Schwab KV, O'Malley DM, Fowler JM, Copeland LJ, Cohn DE. Prospective evaluation of prognostic significance of the tumor-free distance from uterine serosa in surgically staged endometrial adenocarcinoma. *Gynecol Oncol*. 2009;112(1):146-149.
- Chattopadhyay S, Galaal KA, Patel A, et al. Tumour-free distance from serosa is a better prognostic indicator than depth of invasion and percentage myometrial invasion in endometrioid endometrial cancer. *BJOG*. 2012;119(10):1162-1170.
- Ozbilen O, Sakarya DK, Bezircioglu I, Kasap B, Yetimalar H, Yigit S. Comparison of myometrial invasion and tumor free distance from uterine serosa in endometrial cancer. *Asian Pac J Cancer Prev*. 2015;16(2):519-522.
- Singh N, Hirschowitz L, Zaino R, et al. Pathologic prognostic factors in endometrial carcinoma (other than tumor type and grade). *Int J Gynecol Pathol*. 2019;38(Suppl 1):S93-S113.
- Peters EEM, Bartosch C, McCluggage WG, et al. Reproducibility of lymphovascular space invasion (LVSI) assessment in endometrial cancer. *Histopathology*. 2019;75(1):128-136.
- McCluggage WG. Pathologic staging of endometrial carcinomas: selected areas of difficulty. *Adv Anat Pathol*. 2018;25(2):71-84.
- Soslow RA. Practical issues related to uterine pathology: staging, frozen section, artifacts, and lynch syndrome. *Mod Pathol*. 2016;29(Suppl 1):S59-S77.
- Pifer PM, Bhargava R, Patel AK, et al. Is the risk of substantial LVSI in stage I endometrial cancer similar to PORTEC in the north American population? – a single-institution study. *Gynecol Oncol*. 2020;159(1):23-29.
- Krizova A, Clarke BA, Bernardini MQ, et al. Histologic artifacts in abdominal, vaginal, laparoscopic, and robotic hysterectomy specimens: a blinded, retrospective review. *Am J Surg Pathol*. 2011;35(1):115-126.
- Bosse T, Peters EE, Creutzberg CL, et al. Substantial lymph-vascular space invasion (LVSI) is a significant risk factor for recurrence in endometrial cancer—a pooled analysis of PORTEC 1 and 2 trials. *Eur J Cancer*. 2015;51(13):1742-1750.
- Barnes EA, Martell K, Parra-Herran C, Taggar AS, Donovan E, Leung E. Substantial lymphovascular space invasion predicts worse outcomes in early-stage endometrioid endometrial cancer. *Brachytherapy*. 2021;20(3):527-535. doi:10.1016/j.brachy.2020.12.006
- Malpica A, Euscher ED, Hecht JL, et al. Endometrial carcinoma, grossing and processing issues: recommendations of the International Society of Gynecologic Pathologists. *Int J Gynecol Pathol*. 2019;38:S9-S24.
- McCluggage WG, Hirschowitz L, Wilson GE, et al. Significant variation in the assessment of cervical involvement in endometrial carcinoma: an interobserver variation study. *Am J Surg Pathol*. 2011;35(2):289-294.
- Zaino RJ, Abendroth C, Yemelyanova A, et al. Endocervical involvement in endometrial adenocarcinoma is not prognostically significant and the pathologic assessment of the pattern of involvement is not reproducible. *Gynecol Oncol*. 2013;128(1):83-87.
- Jobsen JJ, Naudin Ten Cate L, Lybeert ML, et al. Outcome of endometrial cancer stage IIIA with adnexa or serosal involvement only. *Obstet Gynecol Int*. 2011;2011:962518. doi:10.1155/2011/962518
- Heitz F, Amant F, Fotopoulou C, et al. Synchronous ovarian and endometrial cancer—an international multicenter case-control study. *Int J Gynecol Cancer*. 2014;24(1):54-60.
- Anglesio MS, Wang YK, Maassen M, et al. Synchronous endometrial and ovarian carcinomas: evidence of clonality. *J Natl Cancer Inst*. 2016;108(6):djv428.
- Schultheis AM, Ng CK, De Filippo MR, et al. Massively parallel sequencing-based clonality analysis of synchronous endometrioid endometrial and ovarian carcinomas. *J Natl Cancer Inst*. 2016;108(6):djv427.
- Concin N, Creutzberg CL, Vergote I, et al. ESGO/ESTRO/ESP guidelines for the management of patients with endometrial carcinoma. *Virchows Arch*. 2021;478:153-190.
- Medeiros F, Muto MG, Lee Y, et al. The tubal fimbria is a preferred site for early adenocarcinoma in women with familial ovarian cancer syndrome. *Am J Surg Pathol*. 2006;30(2):230-236.
- Turashvili G, Gómez-Hidalgo NR, Flynn J, et al. Risk-based stratification of carcinomas concurrently involving the endometrium and ovary. *Gynecol Oncol*. 2019;152(1):38-45.
- Brierley JD, Gospodarowicz MK, Wittekind C, eds. *Skin tumours. UICC TNM Classification of Malignant Tumours*. 8th ed. Wiley; 2016.
- Amin MB, Greene FL, Edge SB, et al. The eighth edition AJCC cancer staging manual: continuing to build a bridge from a population-based to a more “personalized” approach to cancer staging. *CA Cancer J Clin*. 2017;67(2):93-99. doi:10.3322/caac.21388

35. Blakely M, Liu Y, Rahaman J, et al. Sentinel lymph node ultra-staging as a supplement for endometrial cancer intraoperative frozen section deficiencies. *Int J Gynecol Pathol.* 2019;38(1):52-58.
36. Euscher E, Sui D, Soliman P, et al. Ultrastaging of sentinel lymph nodes in endometrial carcinoma according to use of 2 different methods. *Int J Gynecol Pathol.* 2018;37(3):242-251.
37. Kim CH, Soslow RA, Park KJ, et al. Pathologic ultrastaging improves micrometastasis detection in sentinel lymph nodes during endometrial cancer staging. *Int J Gynecol Cancer.* 2013;23(5):964-970.
38. León-Castillo A, de Boer SM, Powell ME, et al. Molecular classification of the PORTEC-3 trial for high-risk endometrial cancer: impact on prognosis and benefit from adjuvant therapy. *J Clin Oncol.* 2020;38:3388-3397. doi:10.1200/JCO.20.00549
39. Kandoth C, Schultz N, Cherniack AD, et al. Cancer genome atlas research network. Integrated genomic characterization of endometrial carcinoma. *Nature.* 2013;497:67-73.
40. Piulats JM, Guerra E, Gil-Martín M, et al. Molecular approaches for classifying endometrial carcinoma. *Gynecol Oncol.* 2017;145:200-207.
41. Talhouk A, McConechy MK, Leung S, et al. A clinically applicable molecular-based classification for endometrial cancers. *Br J Cancer.* 2015;113:299-310.
42. Talhouk A, McConechy MK, Leung S, et al. Confirmation of ProMisE: a simple, genomics-based clinical classifier for endometrial cancer. *Cancer.* 2017;123:802-813.
43. Stelloo E, Nout RA, Osse EM, et al. Improved risk assessment by integrating molecular and clinicopathological factors in early-stage endometrial cancer—combined analysis of the PORTEC cohorts. *Clin Cancer Res.* 2016;22:4215-4224.
44. León-Castillo A, Gilvazquez E, Nout R, et al. Clinicopathological and molecular characterisation of 'multiple-classifier' endometrial carcinomas. *J Pathol.* 2020;250:312-322.
45. Vermij L, Smit V, Nout R, Bosse T. Incorporation of molecular characteristics into endometrial cancer management. *Histopathology.* 2020;76:52-63.
46. Church DN, Stelloo E, Nout RA, et al. Prognostic significance of POLE proofreading mutations in endometrial cancer. *J Natl Cancer Inst.* 2015;107(1):402.
47. León-Castillo A, Britton H, McConechy MK, et al. Interpretation of somatic POLE mutations in endometrial carcinoma. *J Pathol.* 2020;250:323-335.
48. Van Gool IC, Rayner E, Osse EM, et al. Adjuvant treatment for POLE proofreading domain mutant cancers: sensitivity to radiotherapy, chemotherapy, and nucleoside analogues. *Clin Cancer Res.* 2018;24:3197-3203.
49. Le DT, Durham JN, Smith KN, et al. Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade. *Science.* 2017;357:409-413.
50. Reijnen C, Küsters-Vandeveldt HVN, Prinsen CF, et al. Mismatch repair deficiency as a predictive marker for response to adjuvant radiotherapy in endometrial cancer. *Gynecol Oncol.* 2019;154:124-130.
51. Mirza MR, Chase DM, Slomovitz BM, et al. Dostarlimab for primary advanced or recurrent endometrial cancer. *N Engl J Med.* 2023;388:2145-2158. doi:10.1056/NEJMoa2216334
52. Eskander RN, Sill MW, Beffa L, et al. Pembrolizumab plus chemotherapy in advanced endometrial cancer. *N Engl J Med.* 2023;388:2159-2170. doi:10.1056/NEJMoa2302312
53. Ouyang C, Frimer M, Hou LY, Wang Y, Goldberg GL, Hou JY. Malignant endometrial polyps in uterine serous carcinoma: the prognostic value of polyp size and lymphovascular invasion. *Int J Gynecol Cancer.* 2018;28:524-528.
54. Assem H, Rottmann D, Finkelstein A, et al. Minimal uterine serous carcinoma and endometrial polyp: a close clinicopathological relationship. *Hum Pathol.* 2021;118:1-8.
55. Hui P, Kelly M, O'Malley DM, Tavassoli F, Schwartz PE. Minimal uterine serous carcinoma: a clinicopathological study of 40 cases. *Mod Pathol.* 2005;18:75-82.
56. Rabban JT, Zaloudek CJ. Minimal uterine serous carcinoma: current concepts in diagnosis and prognosis. *Pathology.* 2007;39:125-133.
57. Xu H, Cui SS, Ran L, et al. Incidence of omental metastasis in uterine serous carcinoma: a systematic review and meta-analysis. *J Gynecol Obstet Hum Reprod.* 2022;51:102395.
58. Prat J. Prognostic parameters of endometrial carcinoma. *Hum Pathol.* 2004;35:649-662.
59. Salvesen HB, Haldorsen IS, Trovik J. Markers for individualised therapy in endometrial carcinoma. *Lancet Oncol.* 2012;13(8):e353-e361.
60. dos Reis R, Burzawa JK, Tsunoda AT, et al. Lymphovascular space invasion portends poor prognosis in low-risk endometrial cancer. *Int J Gynecol Cancer.* 2015;25:1292-1299.
61. Veade AE, Foote J, Ehrisman J, et al. Associations between lymphovascular space invasion, nodal recurrence, and survival in patients with surgical stage I endometrioid endometrial adenocarcinoma. *World J Surg Oncol.* 2019;17:80.
62. Tortorella L, Restaino S, Zannoni GF, et al. Substantial lymphovascular space invasion (LVSI) as predictor of distant relapse and poor prognosis in low-risk early-stage endometrial cancer. *J Gynecol Oncol.* 2021;32(2):e11.
63. Zhan X, Li L, Wu M, Lang J. The prognosis of stage IA synchronous endometrial endometrioid and ovarian carcinomas. *Arch Gynecol Obstet.* 2019;300:1045-1052.
64. Matsuo K, Machida H, Frimer M, et al. Prognosis of women with stage I endometrioid endometrial cancer and synchronous stage I endometrioid ovarian cancer. *Gynecol Oncol.* 2017;147:558-564.
65. Yoneoka Y, Yoshida H, Ishikawa M, et al. Prognostic factors of synchronous endometrial and ovarian endometrioid carcinoma. *J Gynecol Oncol.* 2019;30(1):e7.
66. Peters EEM, León-Castillo A, Smit VTHBM, et al. Defining substantial Lymphovascular space invasion in endometrial cancer. *Int J Gynecol Pathol.* 2022;41(3):220-226. doi:10.1097/PGP.0000000000000806
67. Stålbjerg K, Bjurberg M, Borgfeldt C, et al. Lymphovascular space invasion as a predictive factor for lymph node metastases and survival in endometrioid endometrial cancer – a Swedish gynecologic cancer group (SweGCG) study. *Acta Oncol.* 2019;58(11):1628-1633. doi:10.1080/0284186X.2019.1643036
68. Peters EEM, León-Castillo A, Hogdall E, et al. Substantial lymphovascular space invasion is an adverse prognostic factor in high-risk endometrial cancer. *Int J Gynecol Pathol.* 2022;41(3):227-234. doi:10.1097/PGP.0000000000000805
69. Guntupalli SR, Zigelboim I, Kizer NT, et al. Lymphovascular space invasion is an independent risk factor for nodal disease and poor outcomes in endometrioid endometrial cancer. *Gyn Oncol.* 2012;124:31-35.
70. de Boer SM, Powell ME, Mileshekin L, et al. Adjuvant chemoradiotherapy versus radiotherapy alone in women with high-risk endometrial cancer (PORTEC-3): patterns of recurrence and post-hoc survival analysis of a randomised phase 3 trial. *Lancet Oncol.* 2019;20(9):1273-1285. doi:10.1016/S1470-2045(19)30395-X
71. Page BR, Pappas L, Cooke EW, Gaffney DK. Does the FIGO 2009 endometrial cancer staging system more accurately correlate with clinical outcome in different histologies? Revised staging, endometrial cancer, histology. *Int J Gynecol Cancer.* 2012;22(4):593-598. doi:10.1097/IGC.0b013e3182412ebd
72. Concin N, Matias-Guiu X, Vergote I, et al. ESGO/ESTRO/ESP guidelines for the management of patients with endometrial carcinoma. *Int J Gynecol Cancer.* 2021;31:12-39. doi:10.1136/ijgc-2020-002230
73. Todo Y, Kato H, Okamoto K, Minobe S, Yamashiro K, Sakuragi N. Isolated tumor cells and micrometastases in regional lymph nodes

- in stage I to II endometrial cancer. *J Gynecol Oncol.* 2016;27(1):e1. doi:10.3802/jgo.2016.27.e1
74. Mueller JJ, Pedra Nobre S, Braxton K, et al. Incidence of pelvic lymph node metastasis using modern FIGO staging and sentinel lymph node mapping with Ultrastaging in surgically staged patients with Endometrioid and serous endometrial carcinoma. *Gynecol Oncol.* 2020;157(3):619-623. doi:10.1016/j.ygyno.2020.03.025
  75. St Clair CM, Eriksson AG, Ducie JA, et al. Low-volume lymph node metastasis discovered during sentinel lymph node mapping for endometrial carcinoma. *Ann Surg Oncol.* 2016;23(5):1653-1659. doi:10.1245/s10434-015-5040-z
  76. Bogani G, Mariani A, Paolini B, Ditto A, Raspagliesi F. Low-volume disease in endometrial cancer: the role of micrometastasis and isolated tumor cells. *Gynecol Oncol.* 2019;153(3):670-675. doi:10.1016/j.ygyno.2019.02.027
  77. Plante M, Stanleigh J, Renaud MC, Sebastianelli A, Grondin K, Grégoire J. Isolated tumor cells identified by sentinel lymph node mapping in endometrial cancer: does adjuvant treatment matter? *Gynecol Oncol.* 2017;146(2):240-246. doi:10.1016/j.ygyno.2017.05.024
  78. Burg L, Timmermans M, van der Aa M, et al. Incidence and predictors of peritoneal metastases of gynecological origin: a population-based study in The Netherlands. *J Gynecol Oncol.* 2020;31(5):1-12.
  79. Li H, Zhang R, Chen C, et al. Prognostic value of different metastatic sites for patients with FIGO stage IVB endometrial cancer after surgery: a SEER database analysis. *J Surg Oncol.* 2020;122:941-948.
  80. Concin N, Matias-Guiu X, Vergote I, et al. ESGO/ESTRO/ESP guidelines for the management of patients with endometrial carcinoma. *Radiother Oncol.* 2021;154:327-353. doi:10.1016/j.radonc.2020.11.018
  81. Betella I, Fumagalli C, Rafaniello Raviele P, et al. A novel algorithm to implement the molecular classification according to the new ESGO/ESTRO/ESP 2020 guidelines for endometrial cancer. *J Gynecol Cancer.* 2022;32:993-1000. doi:10.1136/ijgc-2022-003480

**How to cite this article:** Berek JS, Matias-Guiu X, Creutzberg C, et al. FIGO staging of endometrial cancer: 2023. *Int J Gynecol Obstet.* 2023;162:383-394. doi:10.1002/ijgo.14923

## APPENDIX A

### Members and Associate Members of the FIGO Women's Cancer Committee, 2021–2023

Jonathan S. Berek (Chair), Sarikapan Wilailak (Vice Chair), Sean Kehoe (Past Chair), Rose Anorlu, Joanna Cain, Carien Creutzberg, Christina Fotopoulou, Gerhard Lindeque, Xavier Matias-Guiu, Orla McNally, David Mutch, Aikou Okamoto, Rene Pareja, Tali Pomerantz, Giovanni Scambia, Barbara Schmalfeld, Muna Addulrazak Tahlak.

### MEMBERS OF THE FIGO ENDOMETRIAL CANCER STAGING SUBCOMMITTEE, 2021–2023

Jonathan S. Berek (Chair), Nicole Concin, Carien Creutzberg, Christina Fotopoulou, David Gaffney, Sean Kehoe, Kristina Lindemann, Xavier Matias-Guiu, David Mutch.